Patents by Inventor Andrei W. Konradi

Andrei W. Konradi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TERTIARY CARBOXAMIDE COMPOUNDS
    Publication number: 20240025913
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: October 19, 2021
    Publication date: January 25, 2024
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • Bicyclic compounds
    Patent number: 11866431
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: January 9, 2024
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Pyridine derivatives substituted by heterocyclic ring and amino group
    Patent number: 11771688
    Abstract: Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: October 3, 2023
    Assignee: AMPLYX PHARMACEUTICALS, INC.
    Inventors: Andrei W. Konradi, Jonathan A. Covel, Michael Grey
  • CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230295135
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Application
    Filed: January 17, 2023
    Publication date: September 21, 2023
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • Oxadiazole compounds
    Patent number: 11661403
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: May 30, 2023
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • KETONE INHIBITORS OF LYSINE GINGIPAIN
    Publication number: 20230142714
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Application
    Filed: May 9, 2022
    Publication date: May 11, 2023
    Applicant: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • HETEROARYL COMPOUNDS
    Publication number: 20230106583
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: November 19, 2020
    Publication date: April 6, 2023
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • BICYCLIC COMPOUNDS
    Publication number: 20230061429
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: November 7, 2019
    Publication date: March 2, 2023
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • Certain chemical compositions and methods of use thereof
    Patent number: 11591322
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: February 28, 2023
    Assignee: Algen Biotechnologies, Inc.
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • Benzocarbonyl compounds
    Patent number: 11524943
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 13, 2022
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • BICYCLIC COMPOUNDS
    Publication number: 20220298102
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 22, 2022
    Inventors: Andrei W. KONRADI, Tracy Tzu-Ling Tang LIN
  • CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220289725
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Application
    Filed: April 28, 2022
    Publication date: September 15, 2022
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • Bicyclic compounds
    Patent number: 11420935
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: August 23, 2022
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Bicyclic compounds
    Patent number: 11384049
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: July 12, 2022
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • ARGININE GINGIPAIN INHIBITORS
    Publication number: 20220204457
    Abstract: Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 20, 2020
    Publication date: June 30, 2022
    Inventors: Robert A. Galemmo, Andrei W. Konradi, Casey C. Lynch, Stephen S. Dominy
  • Inhibitors of lysine gingipain
    Patent number: 11332464
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: May 17, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Ketone inhibitors of lysine gingipain
    Patent number: 11325884
    Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: May 10, 2022
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
  • INHIBITORS OF JUN N-TERMINAL KINASE
    Publication number: 20220081427
    Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 17, 2022
    Applicant: IMAGO PHARMACEUTICALS, INC.
    Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
  • Benzosulfonyl compounds
    Patent number: 11192865
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: December 7, 2021
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin
  • Non-fused tricyclic compounds
    Patent number: 11186554
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 30, 2021
    Assignee: VIVACE THERAPEUTICS, INC.
    Inventors: Andrei W. Konradi, Tracy Tzu-Ling Tang Lin